U.S. Attorney asks Novo Nordisk about plant in Denmark

Novo Nordisk ($NVO) is not a company for which regulators often express concerns over manufacturing. But the Denmark-based specialist in diabetes meds says the U.S. Attorney in Massachusetts has subpoenaed it for information about potential manufacturing issues at a plant in Kalundborg. In an email, a company spokesman said Novo has no idea what triggered the request but that it is cooperating. He said the site in Kalundborg, Denmark, comprises several plants which produce insulin, GLP-1 and factor VII. The company said, "Novo Nordisk takes patient safety and product quality very seriously and is confident in the safety of its products." Report